▼ -1.44% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is $73.11, with a high forecast of $86.00 and a low forecast of $55.00. The average price target represents a -1.44% upside from the last price of $74.18.
The current consensus among 13 investment analysts is to hold stock in Alcon. This rating has held steady since February 2020, when it changed from a Buy consensus rating.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.